Breast cancer

Освітня мета: Select the most appropriate treatment/sequence of treatments for patients with HR+ HER2- metastatic breast cancer on a patient-specific level, based on individual patient and disease characteristics.

Спеціальність: Medical oncology, Clinical oncology, (Obstetrics & Gynaecology)

Цільова аудиторія: CME (basic, intermediate); Residents (senior)

Останнє оновлення: February 2025

Фон:

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer is the most common subset of breast cancers. In the metastatic setting, novel therapies have expanded and shifted the treatment landscape, especially in the second- and further-line setting.

Regulatory approval status of endocrine and targeted therapies for HR+ HER2- advanced or metastatic breast cancer (status 18 January 2025)

ABC: advanced breast cancer; AI: aromatase inhibitor; AKT1: AKT serine/threonine kinase 1; ER+: oestrogen receptor-positive; ET: endocrine therapy; HER2-: human epidermal growth factor receptor 2-negative; HR+: hormone receptor-positive; IHC: immunohistochemistry; ISH: in situ hybridisation; LHRH: luteinizing hormone-releasing hormone; MBC: metastatic breast cancer; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN: phosphatase and tensin homolog